Thryv Therapeutics, Inc.
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.lqttrx.com
Clinical Trials
5
Active:0
Completed:2
Trial Phases
2 Phases
Phase 1:3
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Not Applicable
1 (25.0%)Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK, PD, and Comparative Bioavailability of THRV-1268 in Obese Adult Participants
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- Thryv Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT07186946
- Locations
- 🇺🇸
Dr. Vince Clinical Research, Overland Park, Kansas, United States
Observational Study to Describe Health-Related Quality of Life and Measure Disease Burden Among Patients With Long QT Syndrome Types (LQTS) 2 and 3
Not yet recruiting
- Conditions
- Long QT Syndrome Type 3Long QT Syndrome 2
- First Posted Date
- 2025-07-20
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- Thryv Therapeutics, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT07075445
- Locations
- 🇺🇸
East Carolina University, Greenville, North Carolina, United States
Study to Assess the Safety, Tolerability, Pharmacokinetic of Thrv-1268
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Thryv Therapeutics, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT06507839
- Locations
- 🇨🇦
Altasciences, Montreal, Quebec, Canada
Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).
Phase 1
Terminated
- Conditions
- Long QT Syndrome
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Thryv Therapeutics, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT05906732
- Locations
- 🇺🇸
Spaulding Clinical Research, LLC, West Bend, Wisconsin, United States
Phase 1 Study of LQT-1213 in Healthy Adults
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Thryv Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT05759962
- Locations
- 🇺🇸
Altasciences Clinical Los Angeles, Inc., Cypress, California, United States
News
No news found